Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 4/20 | 0.50 |
| ▸ | MAX | P61244 | 4/20 | 0.50 |
| ▸ | EP300 | Q09472 | 3/20 | 0.47 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772518 | 0.96 | MYC (0.47) | MYCMAXEP300NEU3XDH | |
| SCHEMBL15662236 | 0.85 | TSHR (0.56) | NEU3SMN1; SMN2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL23226755 | 0.81 | CYP19A1 (0.54) | SMN1; SMN2RXRARXRBRXRGMEN1 | |
| SCHEMBL5494824 | 0.80 | ACLY (0.58) | NEU3NPSR1SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL14481111 | 0.80 | PDE4A (0.49) | NEU3NR1H4SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL27632253 | 0.76 | MYC (0.51) | MYCMAXEP300XDHNR1H4 | |
| SCHEMBL28607405 | 0.76 | PTPN11 (0.51) | MYCMAXEP300XDHNR1H4 | |
| SCHEMBL567311 | 0.75 | NEU3 (0.63) | NEU3SMN1; SMN2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL29791247 | 0.75 | NEU3 (0.63) | NEU3SMN1; SMN2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL4275354 | 0.75 | CA12 (0.67) | MYCMAXNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193125-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-01-11 | — | — | EP | disclosed |
| EP-2193125-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-01-11 | — | — | EP | disclosed |
| CN-101970420-B | Oxadiazole derivatives | MERCK SERONO SA | 2014-09-24 | — | — | CN | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| CN-101970420-A | Oxadiazole derivatives | MERCK SERONO SA | 2011-02-09 | — | — | CN | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2193125-A2 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | MYC 3932/4885MAX 4327/4885EP300 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.